Cargando…

Momelotinib is a highly potent inhibitor of FLT3-mutant AML

Despite the introduction of more selective FLT3 inhibitors to treat FLT3-mutated acute myeloid leukemia (AML), remissions are short lived, and patients show progressive disease after an initial response. Acquisition of resistance-conferring genetic mutations and growth factor signaling are 2 princip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azhar, Mohammad, Kincaid, Zachary, Kesarwani, Meenu, Ahmed, Arhama, Wunderlich, Mark, Latif, Tahir, Starczynowski, Daniel, Azam, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Myeloid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864657/ https://www.ncbi.nlm.nih.gov/pubmed/34768286 http://dx.doi.org/10.1182/bloodadvances.2021004611

Ejemplares similares

Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML
por: Azhar, Mohammad, et al.
Publicado: (2022)

Repression of TRIM13 by chromatin assembly factor CHAF1B is critical for AML development
por: Dean, Sarai T., et al.
Publicado: (2023)

BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
por: Buelow, Daelynn R., et al.
Publicado: (2022)

Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML
por: Bennett, Joshua, et al.
Publicado: (2023)

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial
por: Sierra, Jorge, et al.
Publicado: (2023)

TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently
por: Kim, Han Sun, et al.
Publicado: (2023)

Engraftment characterization of risk-stratified AML in NSGS mice
por: Díaz de la Guardia, Rafael, et al.
Publicado: (2021)

Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice
por: Muranyi, Andrew, et al.
Publicado: (2022)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
por: Heikamp, Emily B., et al.
Publicado: (2022)

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy
por: Versluis, Jurjen, et al.
Publicado: (2022)

Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
por: Ramaswamy, Kavitha, et al.
Publicado: (2022)

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
por: Zarnegar-Lumley, Sara, et al.
Publicado: (2023)

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity
por: Bazinet, Alexandre, et al.
Publicado: (2023)

Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
por: Angenendt, Linus, et al.
Publicado: (2021)

Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition
por: Saito, Kaori, et al.
Publicado: (2021)

Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency
por: Perez, Monika W., et al.
Publicado: (2021)

Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness
por: Pirillo, Chiara, et al.
Publicado: (2022)

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML
por: Martelli, Maria Paola, et al.
Publicado: (2021)

CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones
por: Houtsma, Roos, et al.
Publicado: (2022)

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS
por: Loke, Justin, et al.
Publicado: (2023)

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation
por: Short, Nicholas J., et al.
Publicado: (2023)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
por: Bill, Marius, et al.
Publicado: (2022)

The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
por: von Palffy, Sofia, et al.
Publicado: (2022)

AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology
por: Klever, Marius-Konstantin, et al.
Publicado: (2023)

The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment
por: Fei, Ming-Yue, et al.
Publicado: (2023)

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
por: de Botton, Stéphane, et al.
Publicado: (2023)

Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML
por: Stasik, Sebastian, et al.
Publicado: (2022)

Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML
por: Nguyen, Nam H. K., et al.
Publicado: (2022)

Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories
por: Borate, Uma, et al.
Publicado: (2023)

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
por: Middeke, Jan M., et al.
Publicado: (2022)

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
por: Weinberg, Olga K., et al.
Publicado: (2022)

HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition
por: Moison, Céline, et al.
Publicado: (2022)

EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment
por: Masamoto, Yosuke, et al.
Publicado: (2022)

Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3A(mut)NPM1(mut) AMLs
por: Donato, Elisa, et al.
Publicado: (2022)

t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity
por: Mueller, Sarah B., et al.
Publicado: (2022)

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
por: Pecquet, Christian, et al.
Publicado: (2023)

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy
por: Schnegg-Kaufmann, Annatina S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pmhesdq68pi2fv82or9k9pctkc